Bernstein Remains a Buy on BeOne Medicines AG (ONC)
BeOne Medicines AG (NASDAQ:ONC) is one of the High Growth International Stocks to Buy Now. On February 9, Rebecca Liang from Bernstein reiterated a Buy rating on the stock with a $414 price target. Earlier, on February 4, Barclays also reiterated a Buy rating on BeOne Medicines AG (NASDAQ:ONC) and raised the price target from $385 to $394.
The bullish sentiment follows the first-in-world approval of BeOne’s Sonrotoclax in China to treat adults with two hard-to-treat blood cancers. These include relapsed/refractory mantle cell lymphoma (MCL) and relapsed/refractory chronic lymphocytic leukemia (CLL). The approval in China was based on the MCL study and CLL/SLL study presented at the 2025 ASH conference.
The MCL study demonstrated 52.4% overall response rate per independent review, and the CLL/SLL study showed 77% ORR per independent review. Management noted that the approval in China is part of a global rollout strategy.
Rebecca Liang from Bernstein believes BeOne Medicines AG (NASDAQ:ONC) to be undervalued considering its pipeline. She noted that “the pipeline is not recognized by the market,” and highlighted Sonrotoclax as “potential best-in-class status.”
BeOne Medicines AG (NASDAQ:ONC), based in Switzerland, is a global oncology company focused on discovering and developing innovative cancer treatments for hematology and solid tumors worldwide.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The most urgent bottleneck for AI now: cheap capital is running dry!
Why UnitedHealth Stock Can Still Gain After This Year's 24% Rally -- Barrons.com
2008 Redux! An Overview of Wall Street’s Hottest Trade: AI CDS
As AI giants are aggressively spending money to expand, the credit market has sounded the alarm. The CDS spreads of chip manufacturers such as Broadcom and Nvidia have surged by over 170% in the past six months. Although ten core AI companies, including Google and Amazon, account for only 8% of the investment-grade index constituents, they bear 16% of the implied credit risk. Chip manufacturers are transforming from technology companies into "concentrated lending institutions," with CDS trading volume increasing by more than 1900% year-over-year.
Crypto prices
More
